FILANA THERAPEUTICS, INC.
FLNA$87M
Micro CapNASDAQPharmaceutical PreparationsPharmaceuticals🇺🇸North AmericaAUSTIN
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
FLNA News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
No drugs found in this phase.
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply